Talquetamab

2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational growth of 6.0%* and adjusted operational growth of 6.1%* 2026 Third-Quarter earnings per share (EPS) of $0.09 reflects a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines; adjusted EPS* of $2.59 also reflects the impact of these M&A deals Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.2 Billion or 7.4% at the midpoint and increasing adjusted EPS* guidance by $0.06 to $11.10 or 2.9% at the midpoint Significant innovation including the market authorization of OTTAVA as the world’s first table-integrated soft tissue robotic system, approval of IMAAVY in warm autoimmune hemolytic anemia (wAIHA), and priority review for RYBREVANT FASPRO for advanced head and neck cancer NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2026. “Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio,” said Joaquin Duato, Chairman and Chief Executive Officer. “In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma. This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade.” Overall financial results Q3 ($ in Millions, except EPS) 2026 2025 % Change Reported Sales $25,399 $23,993 5.9% Net Earnings $210 $5,152 (95.9)% EPS (diluted) $0.09 $2.12 (95.8)% Q3 Non-GAAP* ($ in Millions, except EPS) 2026 2025 % Change Operational Sales 1,2 6.0% Adjusted Operational Sales 1,3 6.1% Adjusted Net Earnings 1,4 $6,339 $6,801 (6.8)% Adjusted EPS (diluted) 1,4 $2.59 $2.80 (7.5)% Free Cash Flow 5,6 ~$15,100 $14,226 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Excludes intangible amortization expense and special items 5 Non-GAAP financial measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings. 6 Third-quarter YTD 2026 is estimated as of October 13, 2026 Note: values may have been rounded Regional sales results Q3 % Change ($ in Millions) 2026 2025 Reported Operational 1,2 Currency Adjusted Operational 1,3 U.S. $14,959 $13,708 9.1% 9.1 - 9.1 International 10,440 10,285 1.5 1.8 (0.3) 1.9 Worldwide $25,399 $23,993 5.9% 6.0 (0.1) 6.1 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: values may have been rounded Segment sales results Q3 % Change ($ in Millions) 2026 2025 Reported Operational 1,2 Currency Adjusted Operational 1,3 Innovative Medicine $16,757 $15,563 7.7% 7.9 (0.2) 8.0 MedTech 8,642 8,430 2.5 2.5 0.0 2.5 Worldwide $25,399 $23,993 5.9% 6.0 (0.1) 6.1 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: values may have been rounded Third-Quarter 2026 segment commentary: Operational sales* reflected below excludes the impact of translational currency. Innovative Medicine Innovative Medicine worldwide operational sales grew 7.9%*, with divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by TREMFYA and new products within Other in Immunology, DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, and ERLEADA in Oncology, and SPRAVATO and CAPLYTA in Neuroscience. Growth was partially offset by STELARA (an approximate 690 basis points impact), SIMPONI/SIMPONI ARIA, and REMICADE in Immunology, as well as OPSUMIT/OPSYNVI in Pulmonary Hypertension, and IMBRUVICA in Oncology. MedTech MedTech worldwide operational sales grew 2.5%*. Growth was primarily driven by electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, as well as trauma in Orthopaedics. Full-year 2026 guidance: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP. ($ in Billions, except EPS) October 2026 July 29, 2026 Adjusted Operational Sales 1,2 Change vs. Prior Year / Mid-point 6.4% – 6.8% / 6.6% 6.2% – 6.8% / 6.5% Operational Sales 2 / Mid-point Change vs. Prior Year / Mid-point $100.5B – $100.9B /$100.7B 6.7% – 7.1% / 6.9% $100.3B – $100.9B / $100.6B 6.5% – 7.1% / 6.8% Estimated Reported Sales 3 / Mid-point Change vs. Prior Year / Mid-point $101.0B – $101.4B / $101.2B 7.2% – 7.6% / 7.4% $100.8B – $101.4B / $101.1B 7.0% – 7.6% / 7.3% Adjusted Operational EPS (Diluted) 2,4 / Mid-point Change vs. Prior Year / Mid-point $10.95 – $11.05 / $11.00 1.5% – 2.4% / 2.0% $10.86 – $11.01 / $10.94 0.7% – 2.1% / 1.4% Adjusted EPS (Diluted) 3,4 / Mid-point Change vs. Prior Year / Mid-point $11.05 – $11.15 / $11.10 2.4% – 3.3% / 2.9% $10.96 – $11.11 / $11.04 1.6% – 3.0% / 2.3% 1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures 2 Non-GAAP financial measure; excludes the impact of translational currency 3 Calculated using Euro Average Rate: October 2026 = $1.15 and July 2026 = $1.15 (Illustrative purposes only) 4 Non-GAAP financial measure; excludes intangible amortization expense and special items Note: percentages may have been rounded Other modeling considerations will be provided on the webcast. Notable announcements in the quarter: The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at , or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at Investor News , as well as Innovative Medicine Newsroom , MedTech News & Events , and . Regulatory Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses 1 Press Release FDA approves IMAAVY ® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients Press Release Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer Press Release Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System Press Release Johnson & Johnson Announces MONARCH™ QUEST 3, Advancing the Latest in Robotically-Assisted Bronchoscopy Press Release Data Releases New Johnson & Johnson ICOTYDE ® (icotrokinra) long-term data demonstrate robust 2- year results in the treatment of adults and adolescents with plaque psoriasis 1 Press Release Johnson & Johnson announces new ICOTYDE™ (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy 1 Press Release Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY ® (nipocalimab-aahu) in generalized myasthenia gravis (gMG) Press Release Johnson & Johnson announces TREMFYA ® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study Press Release Single infusion of CARVYKTI ® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma Press Release New model-based analysis further supports the potential of TECVAYLI ® (teclistamab-cqyv) plus DARZALEX FASPRO ® (daratumumab and hyaluronidase-hj) to redene long-term survival expectations in early line relapsed/refractory multiple myeloma Press Release CAPLYTA ® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study Press Release RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE ® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026 Press Release Johnson & Johnson's RYBREVANT ® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer Press Release Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026 Press Release TECVAYLI ® + TALVEY ® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma Press Release Other New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause 1 Press Release Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September Press Release Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation Press Release Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset Press Release Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation Press Release 1 Subsequent to the quarter Webcast information: Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations . About Johnson & Johnson: At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at . Non-GAAP financial measures: * “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results . Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results . These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results . Note to investors concerning forward-looking statements: This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at , , investor.jnj.com , or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) THIRD QUARTER NINE MONTHS Percent Change Percent Change 2026 2025 Total Operations Currency 2026 2025 Total Operations Currency Sales to customers by segment of business Innovative Medicine U.S. $ 10,447 9,402 11.1 % 11.1 - $ 29,297 26,655 9.9 % 9.9 - International 6,310 6,161 2.4 3.0 (0.6 ) 19,270 17,983 7.2 3.6 3.6 16,757 15,563 7.7 7.9 (0.2 ) 48,567 44,638 8.8 7.4 1.4 MedTech U.S. 4,512 4,306 4.8 4.8 - 13,525 12,902 4.8 4.8 - International 4,130 4,124 0.1 0.1 0.0 12,679 12,089 4.9 2.2 2.7 8,642 8,430 2.5 2.5 0.0 26,204 24,991 4.9 3.5 1.4 U.S. 14,959 13,708 9.1 9.1 - 42,822 39,557 8.3 8.3 - International 10,440 10,285 1.5 1.8 (0.3 ) 31,949 30,072 6.2 3.0 3.2 Worldwide $ 25,399 23,993 5.9 % 6.0 (0.1 ) $ 74,771 69,629 7.4 % 6.0 1.4 Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) THIRD QUARTER NINE MONTHS Percent Change Percent Change 2026 2025 Total Operational Currency 2026 2025 Total Operational Currency Sales to customers by geographic area U.S. $ 14,959 13,708 9.1 % 9.1 - $ 42,822 39,557 8.3 % 8.3 - Europe 5,405 5,440 (0.6 ) 1.0 (1.6 ) 16,979 15,937 6.5 2.3 4.2 Western Hemisphere excluding U.S. 1,385 1,231 12.5 8.0 4.5 3,987 3,604 10.6 4.5 6.1 Asia-Pacific, Africa 3,650 3,614 1.0 1.0 0.0 10,983 10,531 4.3 3.6 0.7 International 10,440 10,285 1.5 1.8 (0.3 ) 31,949 30,072 6.2 3.0 3.2 Worldwide $ 25,399 23,993 5.9 % 6.0 (0.1 ) $ 74,771 69,629 7.4 % 6.0 1.4 Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) THIRD QUARTER 2026 2025 Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers $ 25,399 100.0 $ 23,993 100.0 5.9 Cost of products sold 8,097 31.9 7,303 30.4 10.9 Gross Profit 17,302 68.1 16,690 69.6 3.7 Selling, marketing and administrative expenses 6,285 24.7 5,922 24.7 6.1 Research and development expense 4,652 18.3 3,672 15.3 26.7 In-process research and development impairments 339 1.4 - - Interest (income) expense, net 31 0.1 18 0.1 Other (income) expense, net 5,780 22.8 (478 ) (2.0 ) Restructuring 181 0.7 63 0.3 Earnings before provision for taxes on income 34 0.1 7,493 31.2 (99.5 ) (Benefit from)/Provision for taxes on income (176 ) (0.7 ) 2,341 9.7 (107.5 ) Net earnings $ 210 0.8 $ 5,152 21.5 (95.9 ) Net earnings per share (Diluted) $ 0.09 $ 2.12 (95.8 ) Average shares outstanding (Diluted) 2,448.6 2,428.6 Effective tax rate (517.6 ) % 31.2 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income $ 7,672 30.2 $ 8,436 35.2 (9.1 ) Net earnings $ 6,339 25.0 $ 6,801 28.3 (6.8 ) Net earnings per share (Diluted) $ 2.59 $ 2.80 (7.5 ) Effective tax rate 17.4 % 19.4 % (1) See Reconciliation of Non-GAAP Financial Measures. Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) NINE MONTHS 2026 2025 Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers $ 74,771 100.0 $ 69,629 100.0 7.4 Cost of products sold 24,254 32.4 22,288 32.0 8.8 Gross Profit 50,517 67.6 47,341 68.0 6.7 Selling, marketing and administrative expenses 18,751 25.1 16,923 24.3 10.8 Research and development expense 11,832 15.8 10,413 15.0 13.6 In-process research and development impairments 375 0.5 - - Interest (income) expense, net 136 0.2 (62 ) (0.1 ) Other (income) expense, net 6,405 8.6 (7,692 ) (11.1 ) Restructuring 247 0.3 144 0.2 Earnings before provision for taxes on income 12,771 17.1 27,615 39.7 (53.8 ) Provision for taxes on income 1,792 2.4 5,927 8.6 (69.8 ) Net earnings $ 10,979 14.7 $ 21,688 31.1 (49.4 ) Net earnings per share (Diluted) $ 4.49 $ 8.94 (49.8 ) Average shares outstanding (Diluted) 2,445.8 2,424.8 Effective tax rate 14.0 % 21.5 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income $ 24,153 32.3 $ 24,635 35.4 (2.0 ) Net earnings $ 20,034 26.8 $ 20,206 29.0 (0.9 ) Net earnings per share (Diluted) $ 8.19 $ 8.33 (1.7 ) Effective tax rate 17.1 % 18.0 % (1) See Reconciliation of Non-GAAP Financial Measures. Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures Third Quarter Nine Months Ended (Dollars in Millions Except Per Share Data) 2026 2025 2026 2025 Net Earnings, after tax- as reported $210 $5,152 $10,979 $21,688 Pre-tax Adjustments Litigation related 5,519 15 6,116 (6,894 ) Intangible Asset Amortization expense 1,240 1,048 3,732 3,435 Restructuring related 1 195 168 533 302 Orthopaedics separation related 369 - 746 - Acquisition, integration and divestiture related (34 ) 97 142 475 (Gains)/losses on securities 10 (387 ) (262 ) (327 ) IPR&D impairments 339 - 375 - Other - 2 - 29 Tax Adjustments Tax impact on special item adjustments 2 (1,677 ) (168 ) (2,469 ) 826 Tax legislation and other tax related 168 874 142 672 Adjusted Net Earnings , after tax $6,339 $6,801 $20,034 $20,206 Average shares outstanding (Diluted) 2,448.6 2,428.6 2,445.8 2,424.8 Adjusted net earnings per share (Diluted) $2.59 $2.80 $8.19 $8.33 Operational adjusted net earnings per share (Diluted) $2.61 $8.04 Notes: 1 In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations. The program is expected to be substantially completed by the end of fiscal year 2029 with estimated costs between $650 - $750 million, and include site and supplier exit costs, decommissioning and asset impairment costs. Restructuring expenses of $74 million in the fiscal third quarter of 2026 ($274 million Q3 2026 YTD), were primarily related to asset impairments and exit costs. In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of $80 million were recorded in the fiscal third quarter of 2026 ($194 million Q3 2026 YTD) and $128 million in the fiscal third quarter of 2025 ($157 million Q3 2025 YTD) primarily includes costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026. In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $41 million in the fiscal third quarter of 2026 ($65 million Q3 2026 YTD) and $40 million in the fiscal third quarter of 2025 ($145 million Q3 2025 YTD) includes costs related to market and product exits. This program will be completed as of Q4 2026 at a total cost of approximately $1 billion. 2 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. Contacts Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com Read full story here

全文链接：https://tecdat.cn/?p=46332 原文出处：拓端抖音号@拓端tecdat 关于分析师 在此对 Qing Li 对本文所作的贡献表示诚挚感谢，她在上海财经大学完成了应用统计专业的硕士学位，专注生物医药数据挖掘领域。擅长R、Python、SAS等语言。曾工作于辉瑞（中国）担任clinical programmer，熟练使用SAS软件对临床数据的提取、整理、分析和报告，在医药、生物科技等多个行业有丰富的项目经验。 摘要 本文回答以下核心问题： 1. 中国创新药企出海面临的最大障碍是什么？海外商业化与监管壁垒如何突破？ 2. TCE双抗赛道从血液瘤到自免的商业化兑现路径是怎样的？投资窗口期在哪里？ 3. 小核酸药物能否从降脂单适应症跃迁为多适应症平台型技术？商业化拐点是否已经到来？ 4. 口服VEGF能否颠覆玻璃体注射的千亿美元眼科市场？国产口服VEGF进度如何？ 5. 国产双抗在肾癌、肺癌等大适应症的临床数据能否对标K药？出海竞争力几何？ Abstract: This report examines the strategic landscape of Chinese innovative drug globalization, focusing on three breakthrough areas: TCE bispecific antibodies transitioning from hematological malignancies to autoimmune diseases, small nucleic acid drugs expanding from lipid-lowering to multiple therapeutic areas, and oral VEGF therapies poised to disrupt the billion ophthalmic market. Drawing on seven authoritative industry reports, we analyze clinical milestones, commercialization pathways, and competitive positioning of Chinese biopharma on the global stage. 一 引言 中国创新药产业正处于一个结构性拐点：管线份额突破三成而市场份额不足百分之五，这一剪刀差既构成估值压制，也隐含五至三十四倍的扩张空间。2024年下半年以来，出海逻辑从单点License-out向涵盖海外临床、本土注册与商业化运营的全链条模式跃迁，MNC对中国药企早期管线的平台级合作价格——恒瑞与BMS的152亿美元、石药与阿斯利康的185亿美元——标志着全球制药产业链对中国创新资产的重定价。 同一时期，三条技术主线正在重塑产业版图。TCE双抗在2026年ASCO和EHA会议上公布的血液瘤临床数据达到历史最优水平，正在从血液瘤的百亿美元市场向自免的千亿美元赛道跨越。小核酸药物以英克司兰年销售增长近六成、Lepodisiran实现Lp(a)近九成三降幅的临床数据完成商业化验证，RNAi技术从科学概念转化为业绩引擎。口服VEGF小分子药物的临床推进，则有可能打破玻璃体注射二十年的治疗范式独占，打开一个相当规模的眼科增量市场。 从估值层面观察，截至2026年6月港股创新药PS已从2025年10月初的8.5倍回撤至约4.9倍，处于近一年半约31.2%分位。我们认为，当前估值已大体反映地缘政策风险与流动性轮转的悲观预期，而商业化放量、BD持续性以及重磅单品国际化实质进展将成为估值修复的核心催化。 本报告洞察参考《医药魔方：重塑全球价值，中国创新药出海制胜策略与实践》、《国联民生证券：医药行业小核酸风口之上系列——小核酸临床与商业双兑现》、《国泰君安：医药行业2026ASCO&EHA血液瘤领域研究进展》等和文末100份医药行业研究报告及数据，本文完整报告数据图表和文末最新参考报告合集已分享在交流群，阅读原文查看、进群咨询，定制数据、报告和800+行业人士共同交流和成长。 二 第一章 政策催化与全球格局：中国创新药出海的宏观拐点 一句话商业逻辑 政策确定性叠加全球管线份额优势，中国创新药出海已从概念验证期进入价值兑现期，海外商业化能力短板仍是制约份额提升的核心瓶颈。 2025年以来创新药产业政策的密集信号——国务院办公厅全链条支持文件、药监局审评审批改革深化、突破性治疗药物与附条件批准等加速通道常态化——为产业提供了明确的政策预期。FDA对中国药企的审评态度经历前期调整后趋于稳定，2026年多款国产创新药获批或进入优先审评通道，政策不确定性的边际改善为出海提供了基础条件。 从信息图1（中国创新药出海全景战略图）可以看到，中国在全球创新药管线中的贡献比例已超过三成，尤其在ADC领域近六成的管线由中国企业主导或参与。全球每两条ADC管线中有一条来自中国，但中国药企在全球创新药市场的份额仅约百分之五。这一结构性错配构成了从License-out走向本土化运营的根本商业驱动力。 信息图1：中国创新药出海全景战略图 信息图1图表PDF模板已分享到会员群 从图1（中国创新药全球市场份额环形图）可以看到，全球创新药市场超过百分之八十五的份额仍集中在欧美大型制药公司手中。管线贡献与市场份额的结构性脱节，本质上是商业化能力而非研发能力的差距——中国药企缺乏海外营销网络、定价谈判能量和本地医生关系体系。 图1：中国创新药全球市场份额环形图（环形图CH02） 图1数据EXCEL及图表PDF模板已分享到会员群 从图2（中国创新药出海八大障碍雷达图）可以清晰看到障碍排序：海外商业化能力（重要性评分超过八十六分）和监管壁垒（超过八十一分）构成第一梯队，地缘政治不确定性、海外临床试验能力和知识产权保护（七十八至八十分以上）构成第二梯队。值得注意的是，海外生产和供应链评分相对较低——中国企业在制造端已具备较为扎实的基础。 图2：中国创新药出海八大障碍雷达图（刻度线图CH01） 图2数据EXCEL及图表PDF模板已分享到会员群 本文节选自拓端发布的《2026创新药出海报告：小核酸、TCE及口服VEGF策略》，如需获取全文内容，可进入拓端官网搜索查看。 解读：出海瓶颈从研发端（能不能做出来）转移到商业化端（能不能卖出去和能不能被批准），意味着研发基础能力已经过市场验证。 对创业者和品牌方的建议：海外商业化从团队搭建到产出至少需要两年周期。如果产品临床二期数据积极，现在即应开始储备具有FDA审评沟通经验和跨国药企商业化背景的关键人才。 相关文章 2025医药生物行业报告：创新药、BD交易、小核酸 原文链接：tecdat.cn/?p=44773 更多详细数据和细分赛道分析已整理到会员群，进群可获取全文图表数据及PDF模板。 三 第二章 TCE双抗赛道：血液瘤商业化兑现与自免千亿蓝海 一句话商业逻辑 TCE双抗已在血液瘤验证即用型、高ORR、可控安全性的差异化价值，CD3xCD19单药年销售额突破十六亿美元；真正的预期差在于自免适应症的接棒——市场容量从约四百亿美元扩展至超过两千亿美元，2026年或为这一跃迁的拐点。 从医药健康行业研究《TCE：血液瘤商业化兑现、自免接棒，实体瘤静待技术进一步突破》可以勾勒出一条清晰的三阶段演化路径。 阶段一：血液瘤临床数据全面突破。2026年ASCO和EHA年会上多项关键数据创纪录。三特异性TCE抗体（同时靶向CD3和两个肿瘤抗原）在复发或难治性多发性骨髓瘤中实现百分之百客观缓解率；BCL2抑制剂联合BTK抑制剂总缓解率达到百分之九十八且微小残留病灶阴性率接近百分之百；Teclistamab在难治性骨髓瘤中完全缓解率突破六成五；Talquetamab联合达雷妥尤单抗和泊马度胺的三药方案二十四个月无进展生存率超过八成。 从图3（血液瘤TCE治疗关键临床数据对比）可以看到，这些数据不仅追平了CAR-T的历史成绩，且在可及性和安全性上具备结构性优势——TCE为即用型药物，无需个体化细胞制备周期。 图3：血液瘤TCE治疗关键临床数据对比（阴影条形图CH05） 图3数据EXCEL及图表PDF模板已分享到会员群 从信息图2（TCE双抗从临床突破到商业化价值兑现的三阶段转化路径）可以看到，资本对TCE赛道的重定价正在加速推进。 信息图2：TCE双抗从临床突破到商业化价值兑现的三阶段转化路径 信息图2图表PDF模板已分享到会员群 阶段二：全球资本重燃配置热情。2026年前四个月，全球TCE赛道投融资总额达到一百七十八亿美元，已接近2021年峰值四百一十九亿美元的逾四成。TCE双抗和多抗全球合作交易总额突破八十五亿美元，强生将旗下四款TCE产品列入未来三至五年重磅品种矩阵。资本市场以交易规模印证了赛道扩容的确定性。 阶段三：商业化里程碑实质性落地。从图4（TCE双抗全球市场规模与增长预测）来看，CD3xCD19双抗2025年全球销售额超过十六亿美元，验证了商业化闭环。Talquetamab的销售峰值被投行预测为超过五十亿美元。更为关键的是，TCE正从血液瘤向自身免疫性疾病扩张——类风湿关节炎、系统性红斑狼疮等适应症一旦验证，TAM将从约四百亿美元扩容至超过两千亿美元。 图4：TCE双抗全球市场规模与增长预测（半圆面积比例图CH06） 图4数据EXCEL及图表PDF模板已分享到会员群 解读：TCE的差异化价值在于同时兼具即用型、高缓解率、可控安全性和门诊给药可行性，在真实世界可及性维度上对CAR-T形成结构性优势。对于可及性受限的中基层医疗机构， 对投资者的建议：自免适应症临床数据是TCE赛道估值重构的下一催化剂。若类风湿关节炎、系统性红斑狼疮等大适应症的二期数据在2026年下半年读出并达到预设终点，相关标的的TAM估值框架 四 第三章 小核酸药物：从降脂到慢乙肝的跨越式突破 一句话商业逻辑 小核酸药物正处于从降脂单适应症向多适应症平台型技术跃迁的关键阶段。慢乙肝功能性治愈率约三成、Lp(a)降幅突破九成三的临床数据，叠加英克司兰年销售增长逾五成九的商业验证，表明RNAi技术已完成从科学概念到商业价值的闭环转化。 小核酸药物现阶段兼具确定性收入和平台型成长的双重属性。英克司兰已验证一年两针商业化模式的可行性，而Lepodisiran、Bepirovirsen、Zilebesiran等管线品种则将TAM边界持续向外推移。 从信息图3（小核酸药物六大临床突破与海量未满足需求交汇）可以看到，2026年小核酸赛道在三个方向取得里程碑突破。 信息图3：小核酸药物六大临床突破与海量未满足需求交汇 信息图3图表PDF模板已分享到会员群 国联民生证券《医药行业小核酸风口之上系列——小核酸临床与商业双兑现，MNC持续加码》对六大突破进行了全面梳理，我们认为以下三项最具产业意义。 点击标题查阅往期内容 以下是关于生物医药行业出海的公众号文章链接及相关分析：主要文章链接1. 2024中国生物医药出海现状与趋势蓝皮书 文章链接：http://mp.weixin.qq.com/s/On8R3QlEXzvDeX0cc5K8_w发布时间：2024-09-29核心内容：详细分析了中国医药出口格局，2023年原料药占主导地位（73.1%），制剂、中药类和生化药逐步发展。重点探讨了欧盟、美国、东盟等主要出口市场的特点和挑战。2. 2024年全球生物医药交易报告 文章链接：http://mp.weixin.qq.com/s/-rsIl0Zn2xpHfrmhncBoPg发布时间：2025-03-11核心内容：分析2021-2023年全球生物医药交易趋势，显示已上市药物在交易中数量最突出，交易聚焦有潜力、有效性已证实的品种。企业通过并购拓展研发管线，应对专利悬崖挑战。3. 2025医药生物行业创新与出海专题 文章链接：http://mp.weixin.qq.com/s/sS9UmNyQFWvK50qD4zTZ0Q发布时间：2026-01-21核心内容：包含200+份报告PDF，涵盖创新药、BD交易、小核酸等领域，重点关注医药产业链出海策略和国际化发展路径。行业出海核心洞察出口结构分析 根据最新数据，中国医药出口呈现明显分层结构： - - - -区域市场特点 欧美市场：对制剂质量要求极高，进入门槛高但利润丰厚东盟等新兴市场：地理位置相近，合作密切，市场潜力较大全球布局：企业需要针对不同地区制定个性化市场策略交易趋势与战略转型 2021-2023年全球生物医药交易显示： - - - -发展建议与展望转型升级路径政策支持方向 政府应加强政策支持和监管引导，帮助企业应对不同市场的监管要求，推动医药产业健康、可持续发展。 这些文章为生物医药企业出海提供了全面的市场分析、战略指导和实操建议，值得深入研读。 第一，Lepodisiran单针皮下注射实现Lp(a)降低约九成三。Lp(a)是传统小分子药物和单抗均难以有效靶向的致病蛋白，也是心血管残余风险的最重要独立预测因子。小核酸通过RNAi机制从mRNA层面精准阻断Lp(a)合成，且单针药效可持续半年以上——对终身管理的慢病领域意味着结构性的依从性改善。 第二，Bepirovirsen在慢乙肝领域实现约三成的功能性治愈率。从图5（小核酸药物各适应症临床疗效对比）来看，这一数据是现有核苷（酸）类似物治愈率的数十倍、干扰素的约十倍。慢乙肝全球患者超过两亿五千万，其中相当比例面临肝硬化和肝癌的远期风险，三成治愈率已是该领域几十年来最具实质性的突破。 图5：小核酸药物各适应症临床疗效对比（横向比例条形图CH08） 图5数据EXCEL及图表PDF模板已分享到会员群 第三，英克司兰2025年全球销售额接近十二亿美元，同比增长超过五成九。一年两针的商业化模式已获市场验证，峰值预测超过五十亿美元。如果叠加高血压（Zilebesiran）、Lp(a)（Lepodisiran）、慢乙肝（Bepirovirsen）等后续适应症，小核酸药物的总可寻址市场将突破千亿美元量级。 解读：小核酸的核心壁垒在于递送技术而非适应症选择。一旦肝靶向GalNAc递送系统成熟，所有在肝脏合成或代谢的致病蛋白均可成为靶点。每攻克一个新的递送组织，即解锁一批新的适应症矩阵。从图6（小核酸药物全球管线适应症分布与市场规模）可以看到，管线已覆盖心血管、代谢、肾脏、肝脏、中枢神经系统五大治疗领域。 图6：小核酸药物全球管线适应症分布与市场规模（气泡图CH09） 图6数据EXCEL及图表PDF模板已分享到会员群 对投资者和创业者的建议：小核酸赛道的核心竞争要素集中在递送平台和化学修饰技术的自主知识产权。国内已有企业在GalNAc递送技术上取得突破，建议重点关注具备自主递送知识产权的标的。同时，GalNAc平台的专利壁垒高度集中于Alnylam等头部公司，后来者需在脂质纳米颗粒、抗体偶联小核酸等差异化递送 五 第四章 眼科口服VEGF：千亿美元的范式革命 一句话商业逻辑 从玻璃体腔注射到每日一次口服给药，眼科抗VEGF治疗面临二十年来最深刻的范式转换。全身安全事件率超过八成是玻璃体注射的结构性缺陷，口服VEGF小分子药物正在对这一千亿美元级替代市场进行渗透，国产进度领先企业若在2027年前获批将占据先发优势。 全球年龄相关性黄斑变性患者约一亿九千六百万，中国湿性AMD患者约二百三十三万，临床显著黄斑水肿预计从2025年的一亿八千八百万增长至2045年的超过两亿八千万。这是基数庞大且持续增长的患者池。 从信息图4（从玻璃体注射到口服给药：眼科VEGF范式革命）可以观察到，当前标准疗法存在三个结构性痛点：需每月注射、患者依从性极差、全身安全事件率高达八成以上（其中严重事件约占三成）。 信息图4：从玻璃体注射到口服给药：眼科VEGF范式革命 信息图4图表PDF模板已分享到会员群 国联民生证券《生物医药行业报告：眼科口服VEGF值得关注，海西新药进度靠前》将口服VEGF小分子药物定义为对现有治疗范式的替代性创新。从图7（眼科VEGF治疗方式对比：注射vs口服）来看，口服VEGF通过全身给药实现双眼同时覆盖，每日一次口服的依从性远超月注射模式，且可早期干预以减缓疾病进展。 图7：眼科VEGF治疗方式对比：注射vs口服（灰底比例条形图CH10） 图7数据EXCEL及图表PDF模板已分享到会员群 解读：口服VEGF的核心价值不在于对注射VEGF的替代，而在于创造了一个注射剂覆盖不了的增量市场——因恐惧眼球注射而放弃治疗的早期AMD患者、因行动不便无法频繁到院的老年群体。我们认为，这一增量市场的规模可能 对品牌方的建议：眼科口服VEGF的市场教育成本极低，医生和患者均天然倾向口服给药。关键成功要素集中于安全性数据（尤其是全身VEGF抑制可能引发的血压波动和伤口愈合问题）和定价策略。建议在临床试验设计中前置安全性终点，并将其作为市场准 更多详细数据和细分赛道分析已整理到会员群，进群可获取全文图表数据及PDF模板。 六 第五章 国产双抗临床突破：对标K药的全球竞争力 一句话商业逻辑 国产双抗在非小细胞肺癌、肾癌一线、宫颈癌三大适应症中客观缓解率突破七成、疾病控制率逼近百分之百，数据全面对标甚至部分超越K药标准疗法。我们认为，这不仅是临床数据的胜利，更是License-out谈判中定价权和话语权的核心筹码。 从图8（国产双抗vs K药关键临床数据对比）可以清晰看到国产双抗在多适应症中的疗效对标格局。 图8：国产双抗vs K药关键临床数据对比（圆环图CH04） 图8数据EXCEL及图表PDF模板已分享到会员群 依沃西单抗在非小细胞肺癌10mg/kg剂量组实现超过七成的客观缓解率、百分之百的疾病控制率，在抗PD-1类药物历史数据中属于高水平表现。卡度尼利单抗联合阿昔替尼在肾癌一线治疗中实现超过五成的客观缓解率和超过九成七的疾病控制率。HARMONi-6研究中，依沃西方案十二个月总生存率达到近七成九，为免疫联合化疗在晚期非小细胞肺癌一线治疗中的突破性数据。 解读：这些数据的商业意义在于——当国产双抗在跨研究对比中展现出不劣于甚至优于K药的疗效信号，其License-out交易的定价基准即发生根本性变化。这就是近年中国双抗海外授权交易总额和首付款不断刷新 对投资者的建议：除关注肺癌和肾癌两大适应症的商业化进展外，宫颈癌、胃癌等国产双抗差异化布局的适应症竞争格局更为友好，市场进入壁垒更低， 七 第六章 出海策略与风险管理：从License-out到本土化的路径选择 一句话商业逻辑 中国创新药出海已从以首付款规模为锚的1.0阶段进入以海外商业化能力为锚的2.0阶段。从卖分子到自建海外临床和商业化团队的转型意味着更高的前期资本开支和更大的长期回报——五至三十四倍市场份额增长空间即在这一转型路径上。 从图9（中国创新药出海模式演变趋势）观察，2021至2026年License-out交易仍为中国药企出海主流模式，但本土化运营占比从近乎为零提升至近一成五，且增速仍在攀升。 图9：中国创新药出海模式演变趋势（刻度线图CH03） 图9数据EXCEL及图表PDF模板已分享到会员群 这一转型的驱动力来自经济账：License-out模式下中国企业仅能获得产品最终商业价值的不足两成，而自建海外商业化团队在持续投入二至三年后可将大部分商业价值留存在体内。从图10（出海各模式ROI对比分析）来看，本土化运营在第四年进入正回报区间，第七至八年累计回报为License-out模式的五倍以上。 图10：出海各模式ROI对比分析（半圆环图CH07） 图10数据EXCEL及图表PDF模板已分享到会员群 解读：出海模式选择本质上是能力半径与风险偏好的匹配。年收入不足十亿人民币的中型药企大概率需从License-out起步，但头部企业若未在2027年前完成海外自建团队布局，或面临永久错失份 对创业者的建议：若管线中有一至两个资产进入临床二期，建议即刻储备具备FDA审评沟通经验、海外KOL关系和跨国药企商业化背景的关键人才。海外CMS系统搭建和市场准入谈判至少需要十 八 第七章 风险提示 风险一：地缘政治导致的审评不确定性与市场准入壁垒。中美生物技术竞争已从行业讨论上升为政策变量，BIOSECURE法案等工具性立法的走向直接影响中国药企在FDA的审评周期和市场准入条件。 对决策的影响：海外市场准入需预留至少六至十二个月的额外时间缓冲，CMC合规和供应链需提前满足FDA全流程可追溯要求。 补充：即使药物获得FDA批准，在美国市场的商业化落地——商业保险准入、PBM谈判、医生教育——还需额外十二至十八个月和数千万美元投入，报告对商业化后阶段的时间成本估计偏于乐观。 应对方案：建立并行多市场策略，同步布局欧洲EMA和东南亚等新兴市场作为风险对冲，不将全部资源集中于单一海外市场。 社群支持：会员群可获取最新FDA审评动态跟踪和行业合规案例库，与800+从业者交流海外注册经验。 风险二：TCE双抗的细胞因子释放综合征管理仍是临床推广的核心阻力。TCE的CRS总体可控，但在门诊给药场景下CRS监测和干预对医疗资源配置提出了额外要求，可能制约其在基层医疗机构的推广速度。 对决策的影响：短期内TCE适用场景仍集中于一二线城市大型医学中心，基层渗透节奏将慢于市场乐观预期。 补充：TCE从血液瘤切换到自免适应症时安全窗口显著缩窄——自免患者的基础免疫状态与血液瘤患者差异明显，对CRS的耐受度更低，应在自免临床试验中设定更为保守的剂量爬坡方案。 应对方案：在自免适应症临床试验中前移安全性监测节点，设定更严格的安全性暂停标准。 社群支持：会员群提供TCE安全性管理的行业最佳实践案例分析。 风险三：小核酸药物的肝外递送技术尚未实质性突破，平台拓展性存在天花板。目前获批和核心临床管线均依赖GalNAc肝靶向递送，肝外组织的有效递送面临化学修饰效率和内体逃逸率两大瓶颈。 对决策的影响：未来三至五年小核酸药物的可及市场仍以肝脏合成蛋白相关疾病为主，CNS、肌肉等肝外组织适应症需要更长技术积累周期。 补充：GalNAc递送平台的专利壁垒高度集中，Alnylam等头部公司掌握核心知识产权，后来者面临较高的专利围墙风险，应提前布局脂质纳米颗粒和抗体偶联小核酸等差异化递送技术。 应对方案：在跟进GalNAc技术路线的同时，前置布局差异化递送平台，绕开核心专利约束。 社群支持：会员群提供小核酸递送技术专利地图和最新文献精读，帮助理解技术瓶颈和突破方向。 九 第八章 行动建议 在能力建设维度，出海企业需系统性储备三大核心能力。其一，FDA沟通和注册申报能力——不仅需要一个RA团队，更需要有FDA前审评员或FDA沟通经验的顾问团队支持。其二，海外KOL网络——在目标适应症领域与欧美核心临床专家建立联系，至少需要两年持续投入。其三，CMC国际合规能力——中国企业的CMC体系多为NMPA审评设计，转为FDA合规需在流程、文档和供应商审计等环节进行实质性改造，建议提前十二至十八个月启动。 在认知转型维度，中国企业需完成从中国市场到全球市场的思维切换。一个常见误区是将中国市场的成功路径直接复制到海外。现实是，海外市场的定价逻辑、医生处方习惯和患者支付能力与中国市场存在结构性差异，必须以海外市场的规则来设计商业化路径，而非将国内经验翻译成英文。 在行动落地维度，短期内可启动的三件事：第一，选定一个目标海外市场（建议优先考虑东南亚或中东等新兴市场作为试点），研究当地监管机构的注册路径和要求。第二，在LinkedIn上联系五至十位目标适应症领域的海外KOL，了解其对当前治疗格局的判断。第三，若公司尚无海外CMC规划，立即启动CMC团队的内部评估，对照FDA的CMC技术要求识别差距并制定路线图。 十 对比表：七份核心报告的观点交叉验证 报告名称 核心结论 关键数据 分析视角 数据差异原因 医药魔方《重塑全球价值，中国创新药出海制胜策略与实践》 中国创新药需从单点License-out向全链条出海升级 管线占比超三成，市场份额仅约百分之五 全球化战略 统计范围侧重出海策略而非具体药物临床数据 医药健康行业研究《TCE：血液瘤商业化兑现、自免接棒》 TCE处于从血液瘤向自免赛道的历史性跃迁 CD3xCD19年销超十六亿美元，2026前四月融资超一百七十八亿 赛道商业化 数据更新至2026年5月，时点最新 国泰君安《医药行业2026ASCO&EHA：血液瘤领域研究进展》 血液瘤多项临床数据创史上最优，三抗ORR达100% 三抗Ramantamig ORR百分之百，Talquetamab三药方案24月PFS突破八成 临床数据 聚焦ASCO/EHA临床数据更新 国联民生证券《小核酸风口之上系列》 小核酸从降脂向多适应症平台化跃迁已启动 Lepodisiran Lp(a)降幅九成三，英克司兰销售增五成九 技术与商业双视角 覆盖小核酸全赛道 国联民生证券《眼科口服VEGF值得关注》 口服给药将颠覆眼科抗VEGF治疗范式 玻璃体注射全身安全事件率超八成，全球AMD患者约一亿九千六百万 技术创新 专注眼科单一赛道 医药健康行业研究《引领迭代浪潮，国产创新药迈向全球舞台中央》 国产创新药已具全球竞争力，从追赶者变为引领者 国产双抗ORR突破七成，DCR逼近百分之百 行业全景 综合多维度临床和商业化指标 南京市生物医药产业商业秘密保护工作指南 创新药出海过程中知识产权保护不可忽视 商业秘密保护和专利布局是出海的基础保障 合规视角 侧重合规而非临床/市场分析 获取文末所有报告数据，进交流群，加：tecdat_cn 十一 本专题内的参考报告（PDF）目录 向上滑动阅览 医药行业2026ASCO&EHA：血液瘤领域研究进展（国泰君安，2026） 医药健康行业研究：TCE：血液瘤商业化兑现、自免接棒，实体瘤静待技术进一步突破（2026） 医药行业小核酸风口之上系列——小核酸临床与商业双兑现，MNC持续加码（国联民生证券，2026） 生物医药行业报告：眼科口服VEGF值得关注，海西新药进度靠前（国联民生证券，2026） 重塑全球价值，中国创新药出海制胜策略与实践（医药魔方，2025-2026） 医药健康行业研究：引领迭代浪潮，国产创新药迈向全球舞台中央（2025-2026） 南京市生物医药产业商业秘密保护工作指南 等其他100+份精选医药行业报告已分享至会员群（进群获取完整目录） 十二 文章图表清单 序号 图表名称 图表类型 图1 中国创新药全球市场份额环形图 环形图 图2 中国创新药出海八大障碍雷达图 刻度线图 图3 血液瘤TCE治疗关键临床数据对比 阴影条形图 图4 TCE双抗全球市场规模与增长预测 半圆面积比例图 图5 小核酸药物各适应症临床疗效对比 横向比例条形图 图6 小核酸药物全球管线适应症分布与市场规模 气泡图 图7 眼科VEGF治疗方式对比：注射vs口服 灰底比例条形图 图8 国产双抗vs K药关键临床数据对比 圆环图 图9 中国创新药出海模式演变趋势 刻度线图 图10 出海各模式ROI对比分析 半圆环图 信息图1 中国创新药出海全景战略图 信息图 信息图2 TCE双抗从临床突破到商业化价值兑现的三阶段转化路径 信息图 信息图3 小核酸药物六大临床突破与海量未满足需求交汇 信息图 信息图4 从玻璃体注射到口服给药：眼科VEGF范式革命 信息图 本专题精选行业报告已分享至会员群（进群获取完整目录） 作者系医药行业数据挖掘与行业研究分析师，拥有多年生物医药数据分析和行业研究经验。 报告获取 在公众号后台回复“医药报告”或点击文末“阅读原文”，可免费获取专题所有报告PDF版本。 如需定制本赛道专属品牌洞察报告/商业决策尽职调查/赛道进入可行性研究/全渠道自媒体分发服务，加小助手微信号：tecdat_cn。加入会员群获取更多优质的服务，扫描下面二维码即可加群！